Trial Profile

Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalbavancin (Primary)
Indications Bacterial infections
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

27 Nov 2019 Status changed from recruiting to discontinued.
20 Dec 2018 Planned number of patients changed from 12 to 22.
20 Dec 2018 Planned End Date changed from 1 May 2020 to 31 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com